Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...

P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, ...

Mind-body therapies like meditation, psychotherapy, and deep breathing may help reduce stress levels, potentially reducing ...

KYMR outlines plans to advance its immunology candidates. As of Dec. 31, 2024, KYMR had $850 million in cash that should fund its operations into mid-2027.

Wedbush lowered the firm’s price target on Blueprint Medicines (BPMC) to $124 from $135 and keeps an Outperform rating on the shares. The firm ...

RBC Capital analyst Gregory Renza lowered the firm’s price target on Jasper Therapeutics (JSPR) to $48 from $68 and keeps an Outperform rating ...

Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritin ...

Welcome to the Novartis presentation at the 43rd JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst with JPMorgan. It's my great pleasure to introduce Vas Narasimhan, the CEO ...

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...

Dupixent® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in which type 2 inflammation plays a role EYLEA HD® and EYLEA® ...

Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare ...

urticaria) with chronic course and systemic symptoms (headache, asthenia, itching, and gastrointestinal disorders related to histopathological alterations of gastrointestinal mucosa, borderline ...